Login
$PLX
$3.03 +$0.00 (0.0%) After hours

$PLX 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

Company to host conference call and webcast today at 8:00 a.m. ET

12 Aug 2026 8-K: Results of Operations and Financial Condition

Company to host conference call and webcast today at 8:00 a.m. EDT

25 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

1.Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business.

21 May 2026 8-K: Regulation FD Disclosure

1 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N M a y 2026

13 May 2026 8-K: Results of Operations and Financial Condition

Company to host conference call and webcast today at 8:00 a.m. EDT

18 Mar 2026 8-K: Results of Operations and Financial Condition

Company to host conference call and webcast today at 8:00 a.m. EDT

09 Mar 2026 8-K: Other Events

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)

11 Feb 2026 8-K: Regulation FD Disclosure

1 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N F e b r u a r y 2026 Ex...

30 Jan 2026 8-K: Other Events

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

05 Jan 2026 8-K: Regulation FD Disclosure

CARMIEL, Israel, January 5, 2026 — Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with...

13 Nov 2025 8-K: Results of Operations and Financial Condition

Company to host conference call and webcast today at 8:00 a.m. EST

03 Nov 2025 8-K: Other Events

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU

17 Oct 2025 8-K: Regulation FD Disclosure; Other Events

1 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N O c t o b e r 2025 Exhi...

22 Aug 2025 8-K: Entry into a Material Definitive Agreement

Reference is made to the At The Market Offering Agreement, dated as of February 27, 2023, as amended on March 17, 2025 (the “ATM Agreement”), between Protalix BioTherapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwri...

14 Aug 2025 8-K: Results of Operations and Financial Condition

Company to host conference call and webcast today at 8:30 a.m. EDT

01 Aug 2025 8-K: Other Events

On August 1, 2025, Protalix BioTherapeutics, Inc. (the “Company”) announced the dismissal of a claim against the Company and its Board of Directors (the “Board”). On March 10, 2025, plaintiff Kevin Mathew Thomas (“Plaintiff”) filed a Ver...

21 Jul 2025 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

This EMPLOYMENT AGREEMENT (this “Agreement”) is made effective as of June 13, 2025 (the “Effective Date”), by and between Protalix Ltd., a company organized under the laws of the State of Israel (the “Company”) and Mr. Gilad Mamlok (the ...

26 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

Protalix Biotherapeutics, Inc. (the “Company”) convened its 2025 Annual Meeting of Stockholders (the “Meeting”) at 8:00 A.M. EDT on June 26, 2025 at the offices of Gornitzky & Co., The Vitania Tel Aviv Tower, 20 HaHarash Street, Tel Aviv...

09 May 2025 8-K: Results of Operations and Financial Condition

Company to host conference call and webcast today at 8:30 a.m. EDT

23 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

On April 21, 2025, Eyal Rubin, Sr. Vice President and Chief Financial Officer of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”), provided the Company and the Company’s Board of Directors with six months’ notice of...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support